prof. MUDr. Jiří Mayer, CSc.
Department head, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 3643, 3603 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 1618
2024
-
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
American Journal of Hematology, year: 2024, volume: 99, edition: 4, DOI
-
Expression of the immune checkpoint inhibitors on gamma-delta T cells in chronic myeloid leukemia patients during TKI therapy
Year: 2024, type: Appeared in Conference without Proceedings
-
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience
Annals of hematology, year: 2024, volume: 103, edition: 2, DOI
-
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
American Journal of Hematology, year: 2024, volume: 99, edition: 4, DOI
-
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia
Blood advances, year: 2024, volume: 8, edition: 7, DOI
-
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
Leukemia, year: 2024, volume: 38, edition: 5, DOI
-
MethScore as a new comprehensive DNA methylation-based value refining the prognosis in acute myeloid leukemia
CLINICAL EPIGENETICS, year: 2024, volume: 16, edition: 1, DOI
-
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
Journal of clinical oncology, year: 2024, volume: 42, edition: 5, DOI
-
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes
Blood advances, year: 2024, DOI
-
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Annals of hematology, year: 2024, volume: 103, edition: 7, DOI